Impact of age and vector construct on striatal and nigral transgene expression

Molecular Therapy Methods and Clinical Development

Volumn 3, Issue , 2016, Pages 16082-

  Polinski, Nicole K ^a,b   Manfredsson, Fredric P ^a,c   Benskey, Matthew J ^a   Fischer, D Luke ^a   Kemp, Christopher J ^a   Steece Collier, Kathy ^a,c   Sandoval, Ivette M ^a   Paumier, Katrina L ^a   Sortwell, Caryl E ^a,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c St Mary's Mercy Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DOPAMINE; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; MESSENGER RNA;

ADULT; AGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; HUMAN; IMMUNOCOMPETENT CELL; IN SITU HYBRIDIZATION; INTRANIGRAL DRUG ADMINISTRATION; INTRASTRIATAL DRUG ADMINISTRATION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; TRANSGENE; TROPISM; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS PARTICLE; VIRUS RECOMBINANT; WESTERN BLOTTING; YOUNG ADULT; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADENO ASSOCIATED VIRUS 9; ANIMAL CELL; BRAIN NERVE CELL; FISCHER 344 RAT; GROUPS BY AGE; LENTIVIRINAE; MESENCEPHALON; MICROGLIA; PARKINSON DISEASE; SUBSTANTIA NIGRA PARS RETICULATA; VENTRAL MESENCEPHALON; VIRAL GENE THERAPY;

EID: 85015192351     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2016.82     Document Type: Article

References (62)

1. 1 O'Connor, DM, Boulis, NM, Gene therapy for neurodegenerative diseases. Trends Mol Med 21 (2015), 504–512.
2. 2 Choudhury, SR, Hudry, E, Maguire, CA, Sena-Esteves, M, Breakefield, XO, Grandi, P, Viral vectors for therapy of neurologic diseases. Neuropharmacology, 2016 (epub ahead of print). DOI: 10.1016/j.neuropharm.2016.02.013.
3. 3 Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind randomized, controlled trial. Lancet 9 (2010), 1164–1172.
4. 4 Tuszynski, MH, Yang, JH, Barba, D, U, HS, Bakay, RA, Pay, MM, et al. Nerve growth factor gene therapy: activation of neuronal responses in Alzheimer disease. JAMA Neurol 72 (2015), 1139–1147.
5. 5 Nobre, RJ, Almeida, LP, Gene therapy for Parkinson's and Alzheimer's diseases: from the bench to clinical trials. Curr Pharm Des 17 (2011), 3434–3445.
6. 6 Combs, B, Kneynsberg, A, Kanaan, NM, Gene therapy models of Alzheimer's disease and other dementias. Methods Mol Biol 1382 (2016), 339–366.
7. 7 Fischer, DL, Gombash, SE, Kemp, CJ, Manfredsson, FP, Polinski, NK, Duffy, MF, et al. Viral vector-based modeling of neurodegenerative disorders: Parkinson's disease. Methods Mol Biol 1382 (2016), 367–382.
8. 8 Van der Perren, A, Toelen, J, Taymans, JM, Baekelandt, V., Using recombinant adeno-associated viral vectors for gene expression in the brain. Neuromethods 65 (2012), 47–68.
9. 9 Cummings, JL, Banks, SJ, Gary, RK, Kinney, JW, Lombardo, JM, Walsh, RR, et al. Alzheimer's disease drug development: translational neuroscience strategies. CNS Spectr 18 (2013), 128–138.
10. 10 Stocchi, F, Olanow, CW, Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 28 (2013), 3–7.
11. 11 Maguire, CA, Ramirez, SH, Merkel, SF, Sena-Esteves, M, Breakefield, XO, Gene therapy for the nervous system: challenges and new strategies. Neurotherapeutics 11 (2014), 817–839.
12. 12 Emborg, ME, Moirano, J, Raschke, J, Bondarenko, V, Zufferey, R, Peng, S, et al. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol Dis 36 (2009), 303–311.
13. 13 Palfi, S, Gurruchaga, JM, Ralph, GS, Lepetit, H, Lavisse, S, Buttery, PC, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase ½ trial. Lancet 383 (2014), 1138–1146.
14. 14 Herzog, CD, Brown, L, Gammon, D, Kruegel, B, Lin, R, Wilson, A, et al. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 64 (2009), 602–612 discussion 612.
15. 15 Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 (2000), 767–773.
16. 16 Bartus, RT, Herzog, CD, Chu, Y, Wilson, A, Brown, L, Siffert, J, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord 26 (2011), 27–36.
17. 17 Björklund, A, Kirik, D, Rosenblad, C, Georgievska, B, Lundberg, C, Mandel, RJ, Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 886 (2000), 82–98.
18. 18 Marks, WJ Jr, Bartus, RT, Siffert, J, Davis, CS, Lozano, A, Boulis, N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 9 (2010), 1164–1172.
19. 19 Collier, TJ, Sortwell, CE, Daley, BF, Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J Neurosci 19 (1999), 5563–5573.
20. 20 Collier, TJ, O'Malley, J, Rademacher, DJ, Stancati, JA, Sisson, KA, Sortwell, CE, et al. Interrogating the aged striatum: robust survival of grafted dopamine neurons in aging rats produces inferior behavioral recovery and evidence of impaired integration. Neurobiol Dis 77 (2015), 191–203.
21. 21 Nanou, A, Azzouz, M, Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 175 (2009), 187–200.
22. 22 Reimsnider, S, Manfredsson, FP, Muzyczka, N, Mandel, RJ, Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15 (2007), 1504–1511.
23. 23 Davidson, BL, Stein, CS, Heth, JA, Martins, I, Kotin, RM, Derksen, TA, et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97 (2000), 3428–3432.
24. 24 Leone, P, Shera, D, McPhee, SW, Francis, JS, Kolodny, EH, Bilaniuk, LT, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med, 19, 2012, 165ra163.
25. 25 Wu, K, Meyers, CA, Guerra, NK, King, MA, Meyer, EM, The effects of rAAV2-mediated NGF gene delivery in adult and aged rats. Mol Ther 9 (2004), 262–269.
26. 26 Polinski, NK, Gombash, SE, Manfredsson, FP, Lipton, JW, Kemp, CJ, Cole-Strauss, A, et al. Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. Neurobiol Aging 36 (2015), 1110–1120.
27. 27 Klein, RL, Dayton, RD, Diaczynsky, CG, Wang, DB, Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol Aging 31 (2010), 2091–2102.
28. 28 clinicaltrials.gov. 2015 AAV2-GDNF for Advanced Parkinson s Disease (NCT01621581) www.clinicaltrials.gov/ct2/show/NCT01621581?term=gdnf&rank=1.
29. 29 Gao, J, Miao, H, Xiao, CH, Sun, Y, Du, X, Yuan, HH, et al. Influence of aging on the dopaminergic neurons in the substantia nigra pars compacta of rats. Curr Aging Sci 4 (2011), 19–24.
30. 30 Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10 (2004), 302–317.
31. 31 McFarland, NR, Lee, JS, Hyman, BT, McLean, PJ, Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 109 (2009), 838–845.
32. 32 Kells, AP, Forsayeth, J, Bankiewicz, KS, Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain. Neurobiol Dis 48 (2012), 228–235.
33. 33 Ciesielska, A, Mittermeyer, G, Hadaczek, P, Kells, AP, Forsayeth, J, Bankiewicz, KS, Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol Ther 19 (2011), 922–927.
34. 34 Ryazanov, AG, Nefsky, BS, Protein turnover plays a key role in aging. Mech Ageing Dev 123 (2002), 207–213.
35. 35 Grabinski, TM, Kneynsberg, A, Manfredsson, FP, Kanaan, NM, A method for combining RNAscope in situ hybridization with immunohistochemistry in thick free-floating brain sections and primary neuronal cultures. PLoS One, 10, 2015, e0120120.
36. 36 Yurek, DM, Hasselrot, U, Cass, WA, Sesenoglu-Laird, O, Padegimas, L, Cooper, MJ, Age and lesion-induced increases of GDNF transgene expression in brain following intracerebral injections of DNA nanoparticles. Neuroscience 284 (2015), 500–512.
37. 37 Weller, ML, Stone, IM, Goss, A, Rau, T, Rova, C, Poulsen, DJ, Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuroprotection from moderate but not severe hypoxia-ischemia. Neuroscience 155 (2008), 1204–1211.
38. 38 Cannon, JR, Sew, T, Montero, L, Burton, EA, Greenamyre, JT, Pseudotype-dependent lentiviral transduction of astrocytes or neurons in the rat substantia nigra. Exp Neurol 228 (2011), 41–52.
39. 39 Dodiya, HB, Bjorklund, T, Stansell, J 3rd, Mandel, RJ, Kirik, D, Kordower, JH, Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18 (2010), 579–587.
40. 40 Lippincott-Schwartz, J, Snapp, E, Kenworthy, A, Studying protein dynamics in living cells. Nat Rev Mol Cell Biol 2 (2001), 444–456.
41. 41 Nonnenmacher, M, Weber, T, Intracellular transport of recombinant adeno-associated virus vectors. Gene Ther 19 (2012), 649–658.
42. 42 Summerford, C, Samulski, RJ, Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72 (1998), 1438–1445.
43. 43 Qiu, J, Handa, A, Kirby, M, Brown, KE, The interaction of heparin sulfate and adeno-associated virus 2. Virology 269 (2000), 137–147.
44. 44 Walters, RW, Yi, SM, Keshavjee, S, Brown, KE, Welsh, MJ, Chiorini, JA, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 276 (2001), 20610–20616.
45. 45 Shen, S, Bryant, KD, Brown, SM, Randell, SH, Asokan, A, Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286 (2011), 13532–13540.
46. 46 Shen, S, Bryant, KD, Sun, J, Brown, SM, Troupes, A, Pulicherla, N, et al. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. J Virol 86 (2012), 10408–10417.
47. 47 Hwang, BY, Schaffer, DV, Engineering a serum-resistant and thermostable vesicular stomatitis virus G glycoprotein for pseudotyping retroviral and lentiviral vectors. Gene Ther 20 (2013), 807–815.
48. 48 Shin, S, Tuinstra, HM, Salvay, DM, Shea, LD, Phosphatidylserine immobilization of lentivirus for localized gene transfer. Biomaterials 31 (2010), 4353–4359.
49. 49 Sato, Y, Akimoto, Y, Kawakami, H, Hirano, H, Endo, T, Location of sialoglycoconjugates containing the Sia(alpha)2-3Gal and Sia(alpha)2-6Gal groups in the rat hippocampus and the effect of aging on their expression. J Histochem Cytochem 49 (2001), 1311–1319.
50. 50 Sasaki, T, Akimoto, Y, Sato, Y, Kawakami, H, Hirano, H, Endo, T, Distribution of sialoglycoconjugates in the rat cerebellum and its change with aging. J Histochem Cytochem 50 (2002), 1179–1186.
51. 51 Gombash, SE, Lipton, JW, Collier, TJ, Madhavan, L, Steece-Collier, K, Cole-Strauss, A, et al. Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Mol Ther 20 (2012), 544–554.
52. 52 Ciesielska, A, Hadaczek, P, Mittermeyer, G, Zhou, S, Wright, JF, Bankiewicz, KS, et al. Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses. Mol Ther 21 (2013), 158–166.
53. 53 Samaranch, L, San Sebastian, W, Kells, AP, Salegio, EA, Heller, G, Bringas, JR, et al. AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction. Mol Ther 22 (2014), 329–337.
54. 54 Lowenstein, PR, Yadav, VN, Chockley, P, Castro, M, There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther 22 (2014), 246–247.
55. 55 Leys, C, Ley, C, Klein, O, Bernard, P, Licata, L, Detecting outliers: Do not use standard deviation around the mean, use absolute deviation around the median. J Exp Soc Psychol 49 (2013), 764–766.
56. 56 Benskey, MJ, Manfredsson, FP, Lentivirus production and purification. Methods Mol Biol 1382 (2016), 107–114.
57. 57 Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6 (1999), 973–985.
58. 58 Benskey, MJ, Manfredsson, FP, Intraparenchymal stereotaxic delivery of rAAV and special considerations in vector handling. Methods Mol Biol 1382 (2016), 199–215.
59. 59 Benskey, MJ, Sandoval, IM, Manfredsson, FP, Continuous collection of adeno-associated virus from producer cell medium significantly increases total viral yield. Hum Gene Ther Methods 27 (2016), 32–45.
60. 60 O'Callaghan, JP, Miller, DB, The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol Aging 12 (1991), 171–174.
61. 61 Schmittgen, TD, Livak, KJ, Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3 (2008), 1101–1108.
62. 62 Pfaffl, MW, Horgan, GW, Dempfle, L, Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res, 30, 2002, e36.